|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Levine Cancer InstituteClinical Trials**Lugano 2014 Response Evaluation Tool** | **Subject Name:**  | **MRN:**  | **DOB:**  |
| **Investigator:**  | **Protocol #:**  |
| **Research Contact:**  |
|  | Date of PET:\_\_/\_\_/\_­\_or [ ] N/ADate of CT: \_\_/\_\_/\_\_ or [ ] N/A | **Visit:** [ ]  **Screening** [ ]  **Cycle\_\_\_\_\_** [ ]  **Other** |

|  |
| --- |
| **TARGET LESIONS** |
| **Lesion #** | **Exam Type (CT/MRI)** | **Site of Lesion** | **Lesion Dimensions (cm)** | **SPD** | **PET Status**(Enter “0” for no uptake) |
|  |  |  |  \_\_\_ x \_\_\_\_\_\_\_ = \_\_\_\_\_ | SPD: \_\_\_\_\_ cm2 | SUV Max: \_\_\_\_\_\_\_ |
|  |  |  | \_\_\_\_\_\_ x \_\_\_\_\_\_\_ = \_\_\_\_\_\_ | SUV Max: \_\_\_\_\_\_\_ |
|  |  |  | \_\_\_\_\_\_ x \_\_\_\_\_\_\_ = \_\_\_\_\_\_ | SUV Max: \_\_\_\_\_\_\_ |
|  |  |  | \_\_\_\_\_\_ x \_\_\_\_\_\_\_ = \_\_\_\_\_\_ | SUV Max: \_\_\_\_\_\_\_ |
|  |  |  | \_\_\_\_\_\_ x \_\_\_\_\_\_\_ = \_\_\_\_\_\_ | SUV Max: \_\_\_\_\_\_\_ |
|  |  |  | \_\_\_\_\_\_ x \_\_\_\_\_\_\_ = \_\_\_\_\_\_ | SUV Max: \_\_\_\_\_\_\_ |

|  |
| --- |
| **NON-TARGET LESIONS** |
| **Lesion #** | **Exam Type****(CT, PET, other)** | **Site of Lesion** | **CT Status****(CR, PR, Stable, PD, etc)** | **Not Assessed by CT** | **PET Status**(Enter “0” for no uptake SUV activity) |
|  |  |  |  | **[ ]**  | SUVmax: \_\_\_\_\_\_\_\_\_\_\_ [ ]  Not assessed |
|  |  |  |  | **[ ]**  | SUVmax: \_\_\_\_\_\_\_\_\_\_\_ [ ]  Not assessed |
|  |  |  |  | **[ ]**  | SUVmax: \_\_\_\_\_\_\_\_\_\_\_ [ ]  Not assessed |
|  |  |  |  | **[ ]**  | SUVmax: \_\_\_\_\_\_\_\_\_\_\_ [ ]  Not assessed |
|  |  |  |  | **[ ]**  | SUVmax: \_\_\_\_\_\_\_\_\_\_\_ [ ]  Not assessed |

|  |
| --- |
| **NEW LESIONS** |
| Are there new lesions? [ ]  Yes[ ]  No |
| **Lesion #** | **Lesion Site**  | **CT Scan****Lesion Dimensions (cm)** | **PET Status** |
|  |  | \_\_\_\_\_\_\_\_ x\_\_\_\_\_\_\_\_\_ = \_\_\_\_\_\_\_\_ | SUVmax: \_\_\_\_\_\_\_\_\_\_\_ [ ]  Not assessed |
|  |  | \_\_\_\_\_\_\_\_ x\_\_\_\_\_\_\_\_\_ = \_\_\_\_\_\_\_\_ | SUVmax: \_\_\_\_\_\_\_\_\_\_\_ [ ]  Not assessed |

|  |
| --- |
| **Lugano 2014 – Spleen Assessment** |
| Spleen vertical length: \_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm [ ]  Not assessed by CTSUVmax Activity: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ [ ] SUVmax Avidity not assessed |

|  |
| --- |
| **Lugano 2014 – PET Assessment of Bone Marrow:**  |
| Is there evidence of focal FDG-Avid disease in bone marrow? [ ] Yes [ ] No [ ] Not applicable |

|  |
| --- |
| **PET Uptake Assessment** |
| Mediastinal Blood Pool – SUVmax: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Liver – SUVmax: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| Areas not likely attributable to lymphoma: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| The highest SUVmax result across all lesions assessed at this visit: SUVmax: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | If the score is 4 or 5, and the response is the same score as baseline, what is the FDG uptake compared to baseline:[ ]  Increased [ ]  No Change [ ]  Decreased [ ]  Not evaluable |

|  |
| --- |
| **Lugano Overall 5 Point PET Scale:**  |
| 1. No uptake above background 3. Uptake > mediastinum but ≤ liver 5. Uptake markedly higher than liver and/or new lesions
2. Uptake ≤ mediastinum 4. Uptake moderately > liver X Not evaluable
 |
| **Overall 5-Point Score for This Visit: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** |
| **Response Assessments:**PET Based Response: \_\_\_\_\_\_\_\_\_\_\_\_\_ [ ] Not applicableCT Based Response: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ [ ] Not applicableOverall Response per Lugano: \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_ Investigator Signature Date |

Version 8/11/2021